Qingdao Baheal Medical INC. (301015) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥230.38 Million ≈ $33.71 Million USD) by net assets (CN¥2.76 Billion ≈ $404.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Qingdao Baheal Medical INC. to measure how many days the company can operate on defensive assets alone.
Qingdao Baheal Medical INC. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Qingdao Baheal Medical INC.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qingdao Baheal Medical INC. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Baheal Medical INC. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apex Dynamics Inc.
TW:4583
|
0.035x |
|
ELECTROLUX B ADR/2 SK 5
F:ELXA
|
-0.516x |
|
ST Pharm Co.Ltd
KQ:237690
|
-0.036x |
|
Dauch Corporation
NYSE:DCH
|
-0.043x |
|
Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.
SHG:605016
|
0.022x |
|
Sixth Street Specialty Lending Inc
NYSE:TSLX
|
-0.010x |
|
DXC Technology Co
NYSE:DXC
|
0.074x |
|
Semrush Holdings Inc
NYSE:SEMR
|
0.051x |
Annual Cash Flow Conversion Efficiency for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Qingdao Baheal Medical INC. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Qingdao Baheal Medical INC..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.74 Billion ≈ $401.22 Million |
CN¥934.45 Million ≈ $136.74 Million |
0.341x | +9.07% |
| 2024-12-31 | CN¥2.60 Billion ≈ $381.15 Million |
CN¥813.85 Million ≈ $119.09 Million |
0.312x | +21.91% |
| 2023-12-31 | CN¥3.12 Billion ≈ $456.47 Million |
CN¥799.50 Million ≈ $116.99 Million |
0.256x | +91.06% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.53 Million |
CN¥305.75 Million ≈ $44.74 Million |
0.134x | +60.87% |
| 2021-12-31 | CN¥2.17 Billion ≈ $318.14 Million |
CN¥181.30 Million ≈ $26.53 Million |
0.083x | +206.97% |
| 2020-12-31 | CN¥1.50 Billion ≈ $219.31 Million |
CN¥-116.83 Million ≈ $-17.10 Million |
-0.078x | -321.43% |
| 2019-12-31 | CN¥1.31 Billion ≈ $191.03 Million |
CN¥45.96 Million ≈ $6.73 Million |
0.035x | -31.18% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.76 Million |
CN¥55.50 Million ≈ $8.12 Million |
0.051x | -- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more